HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein. This target structure plays a central role in virus entry into human cells and has therefore long been an important focus for the development of … Read more
In the long battle to create an effective HIV vaccine, scientists have made a major leap forward. A new study shows that a series of vaccines can coax the immune system to produce powerful antibodies capable of blocking a wide range of HIV strains-including those that are typically the hardest to stop. Published in Immunity … Read more
Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral replication by orchestrating nuclear entry through interactions with host nuclear pore complexes (NPCs). Recent research has revealed that HIV-1 CA actively disrupts NPC architecture via phenylalanine-glycine (FG)-repeat nucleoporin interactions, thereby enabling nuclear translocation of viral … Read more
As of the end of 2023, nearly 40 million people worldwide were living with HIV, including approximately 1.2 million in the United States. In the same year, about 630,000 people globally died from AIDS-related illnesses. Although this is a significant decline from previous years, AIDS-related deaths remain a critical global health challenge. While antiretroviral therapy … Read more
A multi-national, multi-institutional study led by Weill Cornell Medicine investigators found little natural resistance to a new HIV therapy called lenacapavir in a population of patients in Uganda. The study, published Jan. 30 in the Journal of Antimicrobial Chemotherapy, adds to growing evidence that lenacapavir may be a powerful new tool in the global anti-HIV … Read more
[1] Global HIV & AIDS statistics — Fact sheet. https://www.unaids.org/en/resources/fact-sheet. [2023-4-20]. [2] Liu X, Wang D, Hu J, Song C, Liao LJ, Feng Y, et al. Changes in HIV-1 subtypes/sub-subtypes, and transmitted drug resistance among ART-Naïve HIV-infected individuals — China, 2004-2022. China CDC Wkly 2023;5(30):664 − 71. https://doi.org/10.46234/ccdcw2023.129. … Read more